Clinical Trial Update: Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Vicinium in non-invasive urothelial carcinoma in situ of the bladder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma in Situ

Drugs mentioned

• Vicinium (etileucel? (Note: Vicinium is an investigational antibody-drug conjugate; if uncertain, use Vicinium as brand and leave generic_null))

Snippet

Sponsor: Sesen Bio, Inc. | Conditions: Urinary Bladder Cancer, Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-05-12